|
Heidelberg Pharma is a wholly owned subsidiary of WILEX AG. WILEX is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange (ISIN DE0006614720). Focused on oncology, WILEX has a broad portfolio of near-to-market therapeutic and diagnostic products for the targeted treatment and specific detection of various types of cancer. The company's therapeutic product candidates are based on antibodies and small molecules. Through its US subsidiary WILEX Inc. in Cambridge, MA, WILEX markets a portfolio of oncological diagnostic tests under the brand Oncogene Science. These in-vitro diagnostics could be used as companion diagnostics in clinical trials and for therapy monitoring. Within the WILEX group Heidelberg Pharma independently carries responsibility for the CRO business and collaborations in the field of ADCs.
WILEX's customers and partners include leading international pharmaceutical companies.
|
